Clostridioides difficile, Cdiff, C-diff, C. difficile, CDI, Clinical Trials, MicrobiomeEducating and Advocating for the Prevention, Treatments, Clinical Trials, Environmental Safety of Clostridioides difficile (C. diff. CDI C. difficile) Infections WorldwideC Diff FoundationC.difficilePrevention of Clostridium difficile clinical studyCdiff

SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream —

— Two Poster Presentations Planned for ASM Microbe 2016, Including Detailed Data from Two SYN-004 Phase 2a Open-Label Clinical Trials —

Synthetic Biologics, Inc. a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced positive topline results from the second Phase 2a open-label clinical trial of SYN-004, the Company’s candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antibiotic-resistant organisms. Results from 14 participants who completed this clinical trial were analyzed to assess the ability of the 150 mg dose of SYN-004 to degrade ceftriaxone when administered alone and with the proton pump inhibitor (PPI), esomeprazole.

To read article in its entirety:

http://ir.syntheticbiologics.com/press-releases/detail/211

C Diff Foundation

Educating and Advocating for the Prevention, Treatments, Clinical Trials, Environmental Safety of Clostridioides difficile (C. diff. CDI C. difficile) Infections Worldwide

Tag Archives: Prevention of Clostridium difficile clinical study

Synthetic Biologics Announced Positive Topline Results From the Second Phase 2a Open-Label Clinical Trial of SYN-004, Prevention of C.diff. Infection (CDI) and Antibiotic-associated Diarrhea (AAD)